Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bac8e144da960387e5d86377c228adc8 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-52 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 |
filingDate |
2006-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6cdd33a449cb139b6fe5b36474a6a81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd75352caad72390e74ea9cce3189c83 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bed030fda7b459208d1905173f190aa |
publicationDate |
2008-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-1940871-A2 |
titleOfInvention |
Protease-resistant forms of vegf-d, method of making and method of use |
abstract |
The present invention provides modified VEGF-D polypeptide variants that are resistant to serine protease processing and methods of making and using the same, as well pharmaceutical compositions comprising the peptide or a polynucleotide encoding the same. The VEGF-D variants comprise a VEGF homology domain, and at least one of (1) a C-terminal propeptide that is not cleavable by a serine protease, and (2) an N-terminal propeptide that is not cleavable by a serine protease. The VEGF-D variants can be made using site- directed mutagenesis. The VEGF-D variants are useful for the treatment of diseases such as cardiovascular disease and primary and secondary lymphedema, and for the prevention of stenosis and restenosis of blood vessels. |
priorityDate |
2005-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |